Skip to main
BIOA

BIOA Stock Forecast & Price Target

BIOA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Bioage Labs is positioned for potential success in the biopharmaceutical industry based on its innovative technology platform, promising drug candidates in development, and strategic collaborations. The company's focus on addressing the underlying molecular causes of aging and chronic inflammation could potentially lead to breakthrough treatments for a variety of age-related diseases. Additionally, Bioage Labs has shown a strong financial standing with collaborations and a well-funded pipeline, mitigating the risks associated with drug development.

Bears say

Bioage Labs is a clinical-stage biopharmaceutical company that is seeking to target the biology of aging in order to develop therapies for metabolic diseases. Their main program, BGE-102, is an oral pill that has shown strong results in reducing high-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation that is linked to cardiovascular events. However, there are several key risks that may affect the success of the company, including competition from other NLRP3 inhibitors, regulatory hurdles, and challenges in commercializing their products. Additionally, their financials show significant operating losses and may require additional funding to continue research and development. Overall, while their approach is promising, the company's uncertain outlook and risks may make it a less attractive investment opportunity.

BIOA has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioAge Labs Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioAge Labs Inc (BIOA) Forecast

Analysts have given BIOA a Buy based on their latest research and market trends.

According to 8 analysts, BIOA has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioAge Labs Inc (BIOA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.